Are Olympic athletes free from cardiovascular diseases? Systematic investigation in 2352 participants from Athens 2004 to Sochi 2014

Context Olympic athletes represent model of success in our society, by enduring strenuous conditioning programmes and achieving astonishing performances. They also raise scientific and clinical interest, with regard to medical care and prevalence of cardiovascular (CV) abnormalities. Objective Our aim was to assess the prevalence and type of CV abnormalities in this selected athlete's cohort. Design, setting and participants 2352 Olympic athletes, mean age 25±6, 64% men, competing in 31 summer or 15 winter sports, were examined with history, physical examination, 12-lead and exercise ECG and echocardiography. Additional testing (cardiac MRI, CT scan) or electrophysiological assessments were selectively performed when indicated. Main outcome measures Prevalence and type of CV findings, abnormalities and diseases found in Olympic athletes over 10 years. Results A subset of 92 athletes (3.9%) showed abnormal CV findings. Structural abnormalities included inherited cardiomyopathies (n=4), coronary artery disease (n=1), perimyocarditis (n=4), myocardial bridges (n=2), valvular and congenital diseases (n=45) and systemic hypertension (n=10). Primary electrical diseases included atrial fibrillation (n=2), supraventricular reciprocating tachycardia (n=14), complex ventricular tachyarrhythmias (non-sustained ventricular tachycardia, n=7; bidirectional ventricular tachycardia, n=1) or major conduction disorders (Wolff-Parkinson-White (WPW), n=1; Long QT syndrome (LQTS), n=2). Conclusions Our study revealed an unexpected prevalence of CV abnormalities among Olympic athletes, including a small, but not negligible proportion of pathological conditions at risk. This observation suggests that Olympic athletes, despite the absence of symptoms or astonishing performances, are not immune from CV disorders and might be exposed to unforeseen high-risk during sport activity.

[1]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[2]  G. Matheson,et al.  The International Olympic Committee (IOC) Consensus Statement on periodic health evaluation of elite athletes March 2009 , 2009, British Journal of Sports Medicine.

[3]  S. Caselli,et al.  Three-dimensional echocardiographic characterization of left ventricular remodeling in Olympic athletes. , 2011, The American journal of cardiology.

[4]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. , 2015, Journal of the American College of Cardiology.

[5]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[6]  B. Maron,et al.  Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. , 2002, Journal of the American College of Cardiology.

[7]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[8]  J. Stockman Trends in Sudden Cardiovascular Death in Young Competitive Athletes After Implementation of a Preparticipation Screening Program , 2008 .

[9]  Barry J Maron,et al.  Evidence for efficacy of the Italian national pre-participation screening programme for identification of hypertrophic cardiomyopathy in competitive athletes. , 2006, European heart journal.

[10]  B. Maron Sudden death in young athletes. , 1980, The New England journal of medicine.

[11]  J. Dvořák,et al.  The International Olympic Committee (IOC) consensus statement on periodic health evaluation of elite athletes: March 2009. , 2009, Journal of athletic training.

[12]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[13]  Wojciech Zareba,et al.  Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia: Proposed Modification of the Task Force Criteria , 2010, Circulation.

[14]  D. Corrado,et al.  Italian cardiological guidelines for sports eligibility in athletes with heart disease: part 1. , 2013, Journal of cardiovascular medicine.

[15]  Nancy M Albert,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, The Journal of thoracic and cardiovascular surgery.

[16]  B. Maron,et al.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.

[17]  B. Maron,et al.  Preparticipation cardiovascular evaluation of the competitive athlete: perspectives from the 30-year Italian experience. , 1995, The American journal of cardiology.

[18]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[19]  R A Levine,et al.  Prevalence and clinical outcome of mitral-valve prolapse. , 1999, The New England journal of medicine.

[20]  N. Al-Attar Faculty Opinions recommendation of 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014 .

[21]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.

[22]  Hein Heidbuchel,et al.  Electrocardiographic interpretation in athletes: the ‘Seattle Criteria’ , 2013, British Journal of Sports Medicine.

[23]  Arturo Evangelista,et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[24]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[25]  A. Ryan,et al.  The Olympic games. , 1956, Journal of the American Medical Association.

[26]  Barry J Maron,et al.  Recommendations for interpretation of 12-lead electrocardiogram in the athlete. , 2009, European heart journal.

[27]  B. Maron,et al.  Outcomes in athletes with marked ECG repolarization abnormalities. , 2008, The New England journal of medicine.

[28]  William Stewart,et al.  Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[29]  B. Maron,et al.  Clinical significance of abnormal electrocardiographic patterns in trained athletes. , 2000, Circulation.

[30]  Jonathan A Drezner,et al.  Incidence of sudden cardiac death in athletes: a state-of-the-art review , 2014, British Journal of Sports Medicine.

[31]  M. Link,et al.  Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Associat , 2015, Journal of the American College of Cardiology.

[32]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[33]  D. Adedinsewo,et al.  Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. , 2015, The American journal of cardiology.